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Abstract
Background: Understanding how brain circuit dysfunctions relate to specific symptoms offers promise for
developing a brain-based taxonomy for classifying psychopathology, identifying targets for mechanistic studies
and ultimately for guiding treatment choice. The goal of the Research Domain Criteria (RDoC) initiative of the
National Institute of Mental Health is to accelerate the development of such neurobiological models of mental
disorder independent of traditional diagnostic criteria. In our RDoC Anxiety and Depression (“RAD”) project we
focus trans-diagnostically on the spectrum of depression and anxiety psychopathology. Our aims are a) to use
brain imaging to define cohesive dimensions defined by dysfunction of circuits involved in reactivity to and
regulation of negatively valenced emotional stimulation and in cognitive control, b) to assess the relationships
between these dimension and specific symptoms, behavioral performance and the real world capacity to
function socially and at work and c) to assess the stability of brain-symptom-behavior-function relationships
over time.
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Methods and design: Here we present the protocol for the “RAD” project, one of the first RDoC studies to use brain
circuit functioning to define new dimensions of psychopathology. The RAD project follows baseline-follow up design.
In line with RDoC principles we use a strategy for recruiting all clients who “walk through the door” of a large
community mental health clinic as well as the surrounding community. The clinic attends to a broad spectrum of
anxiety and mood-related symptoms. Participants are unmedicated and studied at baseline using a standardized
battery of functional brain imaging, structural brain imaging and behavioral probes that assay constructs of threat
reactivity, threat regulation and cognitive control. The battery also includes self-report measures of anxiety and
mood symptoms, and social and occupational functioning. After baseline assessments, therapists in the clinic
apply treatment planning as usual. Follow-up assessments are undertaken at 3 months, to establish the reliability
of brain–based subgroups over time and to assess whether these subgroups predict real–world functional capacity
over time. First enrollment was August 2013, and is ongoing.
Discussion: This project is designed to advance knowledge toward a neural circuit taxonomy for mental disorder.
Data will be shared via the RDoC database for dissemination to the scientific community. The clinical translational
neuroscience goals of the project are to develop brain-behavior profile reports for each individual participant and
to refine these reports with therapist feedback. Reporting of results is expected from December 2016 onward.
Trial registration: ClinicalTrials.gov Identifier: NCT02220309. Registered: August 13, 2014.
Keywords: Research Domain Criteria (RDoC), Brain circuits, Anxiety, Depression, Brain imaging, Emotion, Cognition
Background
Globally, one in 13 people suffer from clinical anxiety
and about one in 21 suffer from clinical depression [1, 2].
Anxiety and depression are the leading causes of disability
and lost productivity worldwide [3]. Despite these alarm-
ing statistics, we still lack a valid classification system that
links underlying neural mechanisms to individual symp-
toms, real-world functional consequences and the implica-
tions for treatment choices. In the current diagnostic
system, the Diagnostic and Statistical Manual, fifth edition
(DSM-5) [4] the broad categories of anxiety and mood
disorders offer a reliable terminology for communicat-
ing between clinicians. The DSM-5 (and earlier editions)
is not designed to reflect valid categories in terms of
underlying neural function. At least 50 % of people have
concurrent diagnoses from more than one category of
anxiety and mood disorder [5–7]. Due to the heterogen-
eity of these categories, it is also possible for two people to
both be diagnosed with an anxiety disorder but share only
one symptom, and the same is the case for depressive dis-
orders. Individuals diagnosed with anxiety and depressive
disorders, and their comorbidity, are also commonly
treated with the same medications or behavioral therapies
[8], reflecting our limited understanding of the distinct
underlying mechanisms that could serve as targets for
each intervention.
The National Institute of Mental Health has launched
the Research Domain Criteria (RDoC) initiative, which
is intended to advance the validity of mental disorder
classification by incorporating neuroscience [9, 10]. The
ultimate goal of the RDOC initiative is to incorporate
neuroscience in ways that will bridge the gap between
research and clinical decision-making by helping to de-
fine cohesive subgroups relevant to treatment selection
and to identifying targets for new interventions. The
RDoC initiative is aligned with the vision for precision
psychiatry [11] and offers an opportunity for an integrative
understanding of mood and anxiety disorder [12].
Supported under the RDoC initiative, the present study
is aimed at advancing a brain circuit-based taxonomy
relevant to the spectrum of anxiety and depression.
Brain imaging research in anxiety and depression has
identified core nodes of large-scale circuits that are dys-
functional in these disorders. Here our primary focus is on
two large-scale neural circuits found to be relevant to the
phenotypes of anxiety and associated mood disorders [11]:
the “negative affect” circuit and the “cognitive control”
circuit (Fig. 1).
“Negative affect” circuit
The negative affect circuit is engaged by negatively valenced
stimuli and comprises subcortical nodes in the amygdala,
brainstem regions, hippocampus and insula and both dorsal
and ventral prefrontal nodes – dorsal medial prefrontal cor-
tex (dmPFC) and dorsal ACC connections as well as ventral
mPFC (vMPFC) and ventral (subgenual and pregenual)-
rostral ACC connections [13, 14]. Dorsal/rostral nodes have
been preferentially implicated in appraisal and expression
of emotion and may be considered an “aversive amplifica-
tion” sub-network [14] whereas the ventral nodes are impli-
cated in automatic regulation of negative emotion [13, 15].
These sub-networks may be engaged even in the absence
of conscious sensory awareness, via direct brainstem inputs
[16] (for meta-analysis [13]). In light of their commonly
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observed co-activation [13], the negative affect circuit could
subserve the perception of negative emotion cues and
the salience circuit, the arousal aspects of feeling these
emotions.
“Cognitive control” circuit
The “cognitive control” circuit comprises the dorsolat-
eral prefrontal cortex (DLPFC), anterior cingulate cortex
(ACC), dorsal parietal cortex (DPC) and precentral gyrus
[11]. Together these regions and their interconnectivity
are implicated in the support of higher cognitive functions
such as working memory and selective attention (for meta-
analysis [17]), evidence from convergent neuroimaging
methods [18]). Under task-specific demands the cognitive
control circuit is implicated in cognitive flexibility [19].
In the current study we use these circuits as the inde-
pendent (rather than dependent) variable to parse neural
circuit-based types of dysfunction in a trans-diagnostic
manner. We conceptualize types that represent extremes
along dimensions of dysfunction within these circuits
and their interactions.
Proposed types of dsyfunction in the “Negative affect”
circuit
We hypothesize that negative affect circuit dsyfunctions
will be expressed as hyper-reactivity in the bottom-up
innervation of the amygdala and insula at one extreme and
loss of top-down regulation of emotion-elicited reactivity at
the other extreme (Fig. 1). These putative biotypes
may contribute to subjectively experienced phenotypes
of “negative bias” and “threat dysregulation” [11].
Amygdala hyper-reactivity elicited by non-conscious
processing of masked threat stimuli has been reported in
current depressive disorder (for review [20]), generalized
anxiety disorder [21], generalized social phobia/anxiety
disorder [21–23], specific phobia [24] and panic disorder
[21, 24]. Mood-congruent hyper-reactivity of the amygdala
has also been observed in response to sad faces [25, 26].
By contrast, the opposite finding of reduced amygdala
activation for positive expressions has been observed in
depressed people [27, 28]. There are also findings of
amygdala hypo- (rather than hyper-) reactivity for threat
stimuli, which may characterize unmedicated participants
Fig. 1 Summary of negative affect and cognitive control circuits and the proposed extremes of dysfunction within these circuits
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who go on to respond to typical first-line antidepressants
[27, 29].
Correspondingly, ACC hypo-activation during the pro-
cessing of threat stimuli has been observed in generalized
anxiety disorder [15, 30] and generalized social anxiety
[30]. Reduced connectivity between the amygdala subgen-
ual/ventral ACC has been observed during the processing
of masked threat stimuli in unmedicated MDD [31],
generalized social anxiety disorder [32] and generalized
anxiety disorder [15].
Proposed types of dsyfunction in the “Cognitive Control”
circuit
We hypothesize that cognitive control circuit dsyfunctions
may also be expressed as hyper-reactivity at one extreme
and hypo-activation reflecting loss of top-down control at
the other extreme. These putative biotypes may contribute
to subjectively experienced phenotypes of “cognitive over-
drive” and “cognitive dyscontrol” [11] (Fig. 1).
Depressed people show hyper-activation of the DLPFC
during working memory and executive function tasks,
which may reflect an attempt at compensation to retain
normal behavior (Fig. 1). DLPFC hyper-activation has
been observed during tasks with an increasing cognitive
demand, but in the absence of performance deficits, in,
medicated MDD [33] and unmedicated MDD [34].
Hyper-activation of the ACC has also been observed in
MDD when participants are performing similarly to
controls (rostral ACC [33]) and this effect persists after
remission.
Dysfunction of the cognitive control circuit may be
elicited by tasks requiring effortful selective processing
of relevant while inhibiting irrelevant stimuli, and sug-
gests a “cognitive loss” type (Fig. 1). Hypo-activation of
the DLPFC and dorsal anterior cingulate cortex (dACC)
has been observed across diagnoses, including depres-
sion [35–37] and social anxiety [38]. Correspondingly,
depression has been associated with a loss of functional
DLPFC-dACC connectivity when cognitive control is re-
quired [36]. Hypo-activity in these nodes of the cognitive
control circuit has been found to persist after recovery
in adult and later-life depression [39] suggesting that a
“cognitive loss” type may have a trait-like status.
Linking brain circuit dysfunction to symptom profiles
It is not yet known how dysfunctions involving the nega-
tive affect and cognitive control circuits relate to specific
features of anxiety and mood symptoms. Here we assess
multiple features of anxiety, depression and general
distress, encompassing constructs of “anxious arousal”, “ap-
prehensive expectations” (and rumination) and anhedonia.
Paralleling the findings for brain imaging of neural circuits,
a wide range of disorders share common symptoms. For
example, multiple anxiety disorders (e.g., specific phobia,
panic and social anxiety) share symptoms of anxious
arousal (implicating dysfunctions in bottom-up threat
reactivity), while other general and trauma-related anxiety
disorders (GAD and PTSD) are accompanied by more
cognitive experiences of anxiety, such as apprehensive
expectations (implicating lack of emotion regulation)
[40, 41]. Data-driven techniques such as factor analysis
may be useful in identifying specific dimensions of
symptoms that cut across traditional diagnoses [42].
The RDoC Anxiety and Depression (“RAD”1) study is
supported by the NIMH RDoC initiative, and designed
to make progress toward a cohesive brain-based taxonomy
relevant to the spectrum of anxiety and associated mood




1. To use brain imaging to identify cohesive
transdiagnostic dimensions of dysfunction in the
“negative affect” circuit for threat reactivity and
regulation, and associated dysfunctions in the
“cognitive control” circuit. We will also assess
interactions between these brain circuit
dysfunctions.
2. To assess whether brain circuit-defined dysfunctions
relate to the severity of specific anxiety and mood
symptoms, such as anxious arousal and apprehensive
expectations.
3. To assess whether these brain circuit-defined
dysfunctions also relate in a cohesive way to behavioral
performance and to real world functions related to
burden of illness, specifically social functioning,
quality of life and work productivity.
Secondary objective
To assess if the brain circuit-defined dimensions predict
change in symptoms and real world functions over time.
Ethical approval
The Institutional Review Boards of Stanford University
and Palo Alto University have approved this protocol.
Informed written consent and permission to publish any
direct quotes from interviews will be obtained from each
participant. Consent will also be obtained to video-record
feedback sessions to be used for training purposes.
Methods and design
We use a baseline-follow up design. Intensive assessments
for all measures of interest are undertaken at the baseline
session and after 12 weeks participants are re-assessed at
follow-up on the symptom and functional outcome mea-
sures (Table 1). We control for medication-free status at
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the baseline session and record in an observational (rather
than experimental) manner any interventions that par-
ticipants were exposed to in the 12-week period be-
tween baseline and follow up. Because this was not an
intervention study, but rather an investigation of the
natural stability of brain-behavior-symptom relationships
over time we do not control treatment type or intensity.
Our clinical center partners use a structured treatment
planning approach based on integrative psychotherapy
principles with pharmacological augmentation and all par-
ticipants recruited from the center are currently receiving
individual therapy.
Participants are free of antidepressant medications and
other medications that could impact the brain imaging
assessments.
Consistent with the goal of RDoC and characterizing
brain imaging-derived (rather than diagnostic) constructs,
screening and exclusion criteria are kept to a minimum.
We do not exclude for cognitive indicators of potential
mild cognitive impairment (MCI) given that such cog-
nitive deficits in many patients are associated with their
anxiety and mood symptoms but are not indicative of
neurodegeneration (for review; [43]). These indicators
are recorded for inclusion as covariates in analyses.
For participants who meet inclusion criteria and are
not screened out by exclusion criteria we schedule a
testing site visit. At the testing site visit brain imaging,
behavioral and self-report/observer-rated assessments
are completed (Table 1).
Recruitment
We aim to enroll 160 participants who comprise a clinical-
community sample. Enrollment commenced in August
2013, and we anticipate enrollment for baseline assess-
ments will be completed in 2017.
We are enrolling patients from the Gronowski Center
(GC), a community mental health training clinic, and in-
dividuals from the immediate surrounding community.
The target of 160 ensures sufficient statistical power and
coverage of the spectrum of anxiety and associated mood
symptoms. Our power calculation is designed to test for
an anticipated regression model with a medium effect size;
approximately .5 (or f2 = .0625). With an alpha level of .05,
a power level of .80, two primary predictors (our R0Is) and
four additional predictors (behavioral and questionnaire
measures) we require at least 158 participants. We have
anticipated screening at least 3 times the target number in
order to achieve a total enrolled sample of 160.
We are not using psychiatric diagnosis as inclusion
criteria. We include participants spanning the dimension
from healthy through sufficiently severe to meet diagnos-
tic criteria.
To demonstrate the spread of coverage from our re-
cruitment strategy, we record diagnosis (or absence of
diagnosis), but do not use this information for primary
analyses. Based on prevalence data from the existing GC
records, we have anticipated the following spectrum of
diagnoses: social anxiety disorder (6 %), generalized anx-
iety disorder (13 %), panic disorder (3 %), agoraphobia
or specific phobia (1 %), post-traumatic stress disorder
(8 %), obsessive compulsive disorder (4 %), major de-
pressive disorder (26 %), persistent depressive disorder
(dysthymia) (12 %), bipolar disorder 1 (5 %), other speci-
fied or unspecified depression or anxiety (5 %).
Inclusion and exclusion criteria
Inclusion criteria are: i) age (18+ years) to focus on the
adult brain, ii) fluent and literate in English in order to
understand task instructions, and iii) currently reporting
distress from anxiety and related mood symptoms. Ex-
clusion criteria are: i) current or lifetime experience of
frank psychosis and/or mania, because the circuit dys-
functions associated with such phenomenology might
obscure interpretation of anxiety and mood-related cir-
cuit dysfunctions, ii) presence of suicidal intent repre-
senting imminent risk as indicated during screening and
on-site assessments, iii) medical condition or neurological
disorder that could impact brain imaging data and render
images difficult to interpret, iv) history of physical brain
injury or blow to the head resulting in loss of conscious-
ness greater than five minutes and which in the judgment
of investigators could interfere with interpretation of brain
imaging assessments, and v) severe impediment to vision,
hearing and/or hand movement, likely to interfere with
the ability to complete the assessments, or follow the
instructions.
We record information about comorbid conditions that
are not part of the exclusion criteria, including substance
use and other general medical conditions. In regard to
substance use disorders, we accept participants who are
using alcohol and substances as a comorbid behavior
Table 1 A summary of the test-retest design and type of data
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given the emphasis on recruiting a representative sample.
A NIH Certificate of Confidentiality that has been granted
to the principal investigator protects participants.
Screening
Participants are screened over the phone during a call
that lasts about 15 min. Oral consent is taken, and study
details are explained. Questions about participant demo-
graphics and inclusion and exclusion criteria are asked.
Inclusion criteria questions include being at least 18 years
of age, having recent symptoms of anxiety or depression,
and speaking English. Exclusion criteria questions in-
clude recently taking psychiatric medications, traumatic
brain injuries, MRI contraindications (e.g., implanted de-
vices, pregnancy, claustrophobia, ferromagnetic material
in the body), and psychosis. At the end of the screening
interview, a determination of the participant’s eligibility
is made with the approval of the principal investigator.
Baseline visit
At the baseline visit we undertake a traditional clinical
interview, using the Mini-International Neuropsychiatric
Interview (MINI-Plus) [44]. We also assess demographics
(including age, sex, education and handedness using the
Edinburgh Handedness Inventory), and prior and current
medical status. Detailed assessments targeting our primary
aims are also undertaken at the unmedicated baseline
visit, and Table 2 provides a tabular summary of these
measures.
1. Clinical interview, medical history and demographics
At baseline the MINI-Plus [44] is used to assess DSM-IV
criteria for anxiety and mood disorder and to confirm
exclusions due to psychosis and/or clinically significant
mania. To ensure currency we also apply DSM-5 cri-
teria to the information gathered at interview. Research
personnel also gather comprehensive information on
past and current medical history and additional socio-
demographic data.
2. Brain imaging
Participants undergo a brain scan protocol that will
include a battery of previously established standardized
paradigms [45].
Paradigms
i) Viewing of threat faces We selected the masked
viewing of threat faces paradigm because it reliably en-
gages negative affect circuitry, is grounded in proposed
mechanisms of anxiety, and has been well established by
the investigators. In the masked condition this paradigm
probes automatic bottom-up activation of the negative
affect circuit [16, 46, 47]. Stimuli are from a standard-
ized series of facial expressions of threat-related emo-
tions (fear, anger), loss related emotions (sadness) and
reward-related emotions (happiness), along with neutral,
modified such that the eyes are presented in the central
position of the image [48]. Stimuli are presented for
16.7 ms, determined to be below the sensory threshold for
conscious identification of emotion, followed immediately
Table 2 A summary of the measures used in the trial to assess circuit function, behavior and self-report and observer rated
symptoms and real-world function
fMRI Paradigms Behavioral Tasks Self and Observer Report
Negative Affect Circuit Clinical Measures Real World Function
Masked Facial Expressions of Threat Threat Identification and Bias Symptoms of anxiety and negative mood: Coping:
Threat Conflict Regulation Threat Conflict Adaptation BAI, PSWQ, BDI, QIDS-SR, DASS, MASQ COPE
Emotion Regulation:
ERQ
Cognitive Control Circuit Symptoms of associated traumatic stress,
impulsivity, and substance use:
Social and Occupational Function:





N-Back Continuous Performance Digit Span Trauma-related risk: Work productivity:
Verbal Learning and Memory ELSQ HPQ
Abbreviations: BAI Beck Anxiety Inventory, PSWQ Penn State Worry Questionnaire, BDI Beck Depression Inventory, QIDS-SR Quick Inventory of Depressive
Symptomatology-Self Report, DASS depression anxiety stress scales, MASQ Mood and Anxiety Symptom Questionnaire, PCL-C Posttraumatic Stress Disorder
CheckList-Civilian Version, BIS Barratt Impulsivity Scale, FTND Fagerstrom Test for Nicotine Dependence, DSM 5 AUD DSM 5 Alcohol Use Disorder, AUDIT alcohol
use disorders identification test, DSM 5 SUD DSM 5 substance use disorder, NM-ASSIST NIDA-Modified Alcohol, Smoking and Substance Involvement Screening
Test, CUDIT Cannabis Use Disorder Identification Test, ELSQ Early Life Stress Questionnaire, COPE Brief COPE, ERQ Emotion Regulation Questionnaire, SOFAS Social
and Occupational Functional Assessment Scale, WHOQOL World Health Organization Quality of Life Scale, SWLS satisfaction with life scale, HPQ World Health
Organization Health and Work Performance Questionnaire
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by a neutral face perceptual mask for 150 ms and an
interstimulus interval of 1233.3 ms. Mask stimuli are
offset by 1° in the direction of each diagonal, randomly, in
order to control for the potential effects of priming due to
the perceptual difference between emotion-neutral and
neutral-neutral target-mask pairs. Using a blocked design,
stimuli will be grouped with eight faces expressing the
same emotion per block and repeated 5 times in a
pseudorandom order [45]. Using behavioral psycho-
physical testing, we have shown that when faces in this
paradigm are presented at or below 20 ms, they meet
signal detection criteria for being at the subliminal
threshold for detection, such that individual participants
cannot detect the presence of the face nor discriminate
the facial expression [48].
To provide a positive control for the masked condition
we also present the same 240 standardized facial expres-
sions described above in an explicit conscious perception
condition. In this condition stimuli will be presented for
500 ms, with an interstimulus interval of 750 ms, also in
a blocked design. The stimulus duration of 500 ms was
based on evidence that this is sufficient time to allow for
conscious elaborative processing of the emotion stimulus.
Conscious discrimination of emotion is consistently above
chance (and close to 100 %) at durations ≥330 msec [48]
and facial expressions of emotion consistently elicit a con-
tagious effect of experiencing the emotion signaled by the
stimulus at durations of 500 ms [49]. Stimulus onset asyn-
chronies are standardized at 1250 ms across both masked
and explicit perception paradigms. No specific behavioral
responses were required during scanning because of the
inclusion of subliminal presentations and our aim to iso-
late activation elicited by emotion stimuli independent of
behavioral task demands. A large meta- analysis of 385
studies has shown passive processing is associated with a
higher probability of activation than an active task [50].
We created a context for participants to continuously view
the faces by instructing them that they would be asked
post-scan questions about these faces. We will control for
active attention to the face stimuli by monitoring alertness
with an eye tracking system.
ii) Threat conflict regulation paradigm We selected the
threat conflict paradigm because it also reliably engages
negative affect circuitry, in this for top-down regulation
of emotional reactivity, and is also well established by
the investigators [15, 51].
In the threat regulation task participants are presented
with a total of 148 happy or fearful facial expressions
[52], while ignoring an overlying word labeling the expres-
sion (“FEAR” or “HAPPY”). The word either matches the
facial expression (congruent) or conflicts with it (incon-
gruent). Each stimulus will be presented for 1000 ms with
a variable interstimulus interval (mean: 4000; range: 3000-
5000 ms). Stimuli will be presented in a psudorandom
order [51].
iii) Go-NoGo paradigm We use the Go-NoGo paradigm
that has been established as a robust probe of the cogni-
tive control circuit [45, 53, 54]. The Go-NoGo paradigm
is used to assess impulsivity (automatically-generated
‘Go’ responses) versus inhibition (‘NoGo’ responses). In
the ‘Go’ trials, participants are required to “press” on
GREEN stimuli (the word “press”), while in the ‘NoGo’
trials; participants withhold presses on RED stimuli.
Stimuli are presented for 500 ms each with an inter-
stimulus interval of 750 ms. Participants are asked to re-
spond via button press as quickly as possible to the Go
stimuli and inhibit their response for the NoGo stimuli.
Reaction times and number of errors on task are used to
evaluate task performance. The design of this paradigm
allows for event-related analysis. The probability of
NoGo stimuli is .33. There are a total of 180 Go and 60
NoGo stimuli presented in a pseudorandom order with
a constraint to ensure that NoGo stimuli are not re-
peated more than 3 times in a row.
iii) N-back Continuous Performance Test As a comple-
ment to the Go-NoGo paradigm used to assay cognitive
control functions we also use an n-back Continuous Per-
formance Test (CPT) to assess sustained attention and se-
lective working memory updating [45]. In the “sustained
attention” target trials, participants press a button when
the same letter appears twice in a row (a ‘1-back’ design).
In the “working memory updating” trials participants are
required to continually update the contents of working
memory in case of a target. In total there are 120 letters (B,
C, D or G) presented sequentially, including 20 sustained
attention targets in yellow, 60 working memory updating
stimuli in yellow and 20 addition “to be ignored” letter in
white which were intended to provide a perceptual baseline
condition. Stimuli are presented for 200 ms each with an
inter-stimulus interval of 2300 ms. Presentation was
pseudorandom, ensuring there were no consecutive target
tones. One fMRI volume per stimulus was acquired.
Acquisition and quantification
i) Functional scans For each paradigm, blood oxygen-
ation level-dependent contrast functional images are
acquired with echo-planar T2*-weighted imaging using
3.0 Tesla GE Signa HDx scanner (GE Healthcare,
Milwaukee, Wisconsin) with a 32-channel head coil. Each
whole brain volume will consist of 45 interleaved 3 mm
thick axial/oblique slices (74 x 74 matrix; TR, 2000 ms;
TE, 27.5 ms; size, 3 x 3 x 3 mm; FOV, 222 mm; flip angle,
77°). 154 volumes will be acquired over 5.03 min and 8 s
for all paradigms but the emotion regulation task. For the
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emotion regulation task a total of 397 volumes will be col-
lected over 13 min 14 s. Three dummy scans are acquired
at the start of each acquisition.
Preprocessing and data analysis is performed using Statis-
tical Parametric Mapping software implemented in Matlab
(SPM8; Wellcome Department of Cognitive Neurology) in
a manner similar to that of our prior publications [27, 45].
Specifically, Motion correction is performed by realigning
and unwarping the fMRI images to the first image of each
task run. Following realignment and unwarping, quality
control diagnostics are completed on the time series data
for each run. Images are normalized to the stereotactic
space of the Montreal Neurological Institute (MNI)
template [55], T1- weighted data are normalized to
standard space using the FMRIB nonlinear registration
tool and the fMRI EPI data are coregistered to the T1
data using FMRIB linear registration tool. Normalization
warps from these two steps are stored for use in functional
to standard space transformations. Global signal is es-
timated using a eroded mask within the ventricles and
white matter and is removed from the motion-
corrected fMRI time series. fMRI data are smoothed
using an 8 mm Gaussian kernel and high-pass filtered
using a cutoff period of 128 s.
To define circuit-based constructs we focus first on
specific nodes in the circuits of interest using a region of
interest (ROI) approach, established previously [56].
With the RO1 approach we identify BOLD-dependent
signal change in the defining nodes of the negative affect
circuit, including amygdala, insula, ACC/mPFC (ventral
and dorsal). Beta values for each ROI are extracted for
each subject for regression analyses. We will also use
functional connectivity analyses to quantify the func-
tional relationships between regions. Further, exploratory
whole brain, voxel-wise analyses are conducted using a
significance threshold of p < 0.05 corrected for multiple
comparisons. Regions of activation are defined according
to the Talairach Atlas. In parallel we study additional
regions as part of the exploratory goals of the study.
ii) Additional exploratory functional analyses Since
we recognize that the amygdala and ACC are part of
more extensive circuits, in the exploratory phase we will
also assess activation in other regions, informed by the
extant literature and any new developments in the field.
iii) Structural scans A high-resolution T1-weighted
structural scan is acquired using a 3D spoiled gradient
echo (SPGR) sequence at the end of the imaging session
for use in normalization of the fMRI data into standard
space. A diffusion scan is also acquired in order to quan-
tify white matter integrity.
3. Behavior
Computerized tests of behavioral performance
Threat identification and bias: The same faces as shown
during fMRI are presented on a computer screen (96
stimuli, 8 different individuals). Identification is recorded
by the verbal labeling of the expressions and the reaction
time to do so. Implicit priming of reaction time to “old/
new” memory recognition of faces, primed by prior expos-
ure to facial expressions of threat versus neutral, to elicit
biases to threat using an established protocol [57]. The
bias to fear is the reaction time difference (in milliseconds)
for priming due to threat minus neutral.
Threat conflict adaption: The Emotional Conflict task
generates reliable reaction time interference [15, 51, 58].
We will quantify reaction time for successive trials, index-
ing adaptive regulation to fear-related conflict.
Go-NoGo: To assess response inhibition we use a previ-
ously established task in which participants respond quickly
to green stimuli and withhold responses to red stimuli [59].
We will also assess cognitive control using additional
behavioral tests of executive function, memory and in-
hibition, including the following:
Digit span. To assess working memory participants are
asked to hold online a span of 2 to 9 digits and then
repeat these digits in order.
Verbal learning and memory. To test immediate and
delayed recall of verbal information (12-word lists),
equivalent to the constructs assessed by the California
Verbal Learning and Memory test.
Verbal Interference test: Using previously established
tests assessing constructs equivalent to those assessed by
the Stroop color/word test [59].
Acquisition and quantification
Each of these behavioral tests runs on a desktop computer,
and does not rely on keyboard skills. The software used to
run the tasks includes standardized task instructions.
Psychometric properties have been established for each
of these tests, including norms, construct validation,
validation against traditional neuropsychological tests
tapping equivalent functions, test-retest reliability, and
consistency across cultures [59–64]. The tests have
been used effectively in patient groups in previous research
by the investigators [65–68].
For each test we record accuracy and reaction time via
the testing software. These data are logged in a file on
the desktop computer under the identification code for
each participant.
4. Self-report and observer-rated measures
Symptoms of anxiety and negative mood
i) Beck Anxiety Inventory (BAI) A 21-item self-report
inventory for measuring the severity of common symptoms
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of anxiety that the participant has had during the past
week, such as numbness and tingling, sweating not due to
heat, and fear of the worst happening [69].
ii) Penn State Worry Questionnaire (PSWQ) A 16-item
questionnaire that assesses items such as “my worries
overwhelm me” and is rated on a likert scale, with scores
ranging from 1 to 80 [70].
iii) Beck Depression Inventory (BDI) A 21-item, self-
report rating inventory that measures symptoms of de-
pression such as hopelessness and irritability, cognitions
such as guilt or feelings of being punished, as well as
physical symptoms such as fatigue, weight loss, and lack
of interest in sex [71].
iv) Quick Inventory of Depressive Symptomatology,
Self-Report (QIDS-SR) A 16-item self-report assessment
of the nine DSM-IV symptom criteria for major depressive
disorder. Individuals rate items as present, mild, moderate
severe, and scores range from 0 to 27 [72].
v) Depression, Anxiety and Stress Scale (DASS) The
DASS is a 42-item self-report scale that assesses symptoms
of depression/anhedonia, anxious arousal and generalized
anxiety (stress) that are not tied to a particular diagnosis.
The DASS has been normed for use in healthy and patient
groups, and validated against other measures of anxiety
such as the BAI described above [73].
iv) Mood and Anxiety Symptom Questionnaire (MASQ)
A 90-item questionnaire based on the tripartite model of
affective disorder which encompasses constructs of
anhedonia, anxious arousal and generalized distress,
equivalent to the DASS, and which has also been used
in healthy and patient groups [74].
Symptoms of associated traumatic stress, impulsivity and
substance use symptoms
i) PTSD CheckList – Civilian Version (PCL-C) A self-
report rating scale for assessing the 17 DSM-IV symp-
toms of PTSD. This version is a general civilian version
that is not linked to a specific event. A total score is
computed by adding the 17 items, so that possible scores
range from 17 to 85 [75].
ii) Barratt Impulsiveness Scale (BIS) A questionnaire
designed to assess the personality/behavioural construct
of impulsiveness [76] that may reflect subclinical mania
and related experiences.
iii) Fagerström Nicotine Dependence Scale (FNDS) A
short 6-item instrument used for assessing the intensity
of physical nicotine addiction [77].
iv) DSM-5 alcohol use disorder A 12-item questionnaire
assessing alcohol use based on the DSM-5 criteria [4].
v) Cannabis Use Disorder Identification Test – Revised
(CUDIT-R) A cannabis misuse screening tool containing
8 items, two from each of the domains of consumption,
cannabis problems (abuse), dependence, and psycho-
logical features [78].
vi) DSM-5 substance abuse disorder An 11-item ques-
tionnaire assessing substance use disorders based on the
DSM-5 [4].
vii) NIDA-Modified Alcohol, Smoking, and Substance
Involvement Screening Test (NM-ASSIST) A 15-item
measure adapted from the World Health Organization
(WHO) Alcohol, Smoking and Substance Involvement
Screening Test, used to assess prescription medicine and
illicit substance use in adults age 18 and older [79].
Trauma-related risk factors
Early Life Stress Questionnaire (ELSQ): A 19-item ques-
tionnaire used to retrospectively assess exposure to early
life stress, by ascertaining whether the participant had
experienced physical, emotional, or sexual abuse as well
as other traumatic experiences such as sustained bully-
ing, poverty, divorce, illness, or domestic violence. If a
stressor was present, the participant identified age of on-
set (0-12 years of age) [80].
Real world function and coping
i) Brief COPE A multidimensional coping inventory to
assess the different ways in which people respond to
stress [81].
ii) Emotion Regulation Questionnaire (ERQ) A 10-item
questionnaire designed to assess individual differences in
the habitual use of two emotion regulation strategies:
cognitive reappraisal and expressive suppression [82].
iii) Social Functioning and Adjustment Scale (SOFAS)
The SOFAS is a derivative of the Global Adjustment
Scale and reflects the individual’s level of social and
occupational functioning, rated on a scale from between 0
and 100 [83].
iv) World Health Organization Quality of Life
(WHOQOL) scale This is a 30-item scale that assesses the
psychological, general health, physical and environmental
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aspects of quality of self-reported quality of life, each
assessed out of 100 [84].
v) Satisfaction With Life Scale (SWLS) A short, 5-item
instrument designed to measure global cognitive judg-
ments of satisfaction with one’s life [85].
vi) Health Productivity Questionnaire (HPQ) This is a
14-item scale that assesses productivity at work, and
relative and absolute levels of absenteeism from work as
well as presenteeism (being at work, but unproductive due
to the effects of anxiety and depressive symptoms [86].
Acquisition and quantification
Each self-report measure is presented in a computerized
format. Individual item scores are recorded and then
summed automatically according to symptom cluster and
scale definitions. The only exception to automated scoring
is the SOFAS, which is rated by study coordinators.
Follow-up outcome measures
At 12-week follow-up, we assess change in/stability of
symptoms using the PSWQ, DASS and MASQ, HPQ
and WHOQoL.
Translational outcomes: toward a precision mental health
protocol
Participants are offered the opportunity to partake in a
brief feedback session (i.e., 30 min) with the study princi-
pal investigator, key clinical personnel and their current
therapist. The feedback is based on self-report measures
such as mood and anxiety symptoms, social and occupa-
tional functioning, and behavioral tests of emotion and
cognition. A brief clinical summary of the participant’s
history is provided to the investigator as contextual infor-
mation. The investigator discusses the participant’s profile
on the measures, describes relevant test performance, and
gives recommendations for how this information could be
applied to treatment. Anxiety and depression are examined
from an RDoC perspective incorporating such dimensions
as threat reactivity, threat regulation and cognitive per-
formance; the participant is offered an overview of their
experience based on a neural circuitry perspective. The
participant and their therapist are given the opportun-
ity to ask questions regarding current symptomatology
as related to the neuroimaging and behavioral data. At
the conclusion of the feedback session, the investigator
exits while the participant and therapist consider the
information received. The ultimate goal is to collaborate
on incorporating the feedback into the current treatment
plan. Treatment outcomes such as symptom reduction
and therapy retention will be examined for participants
who receive the feedback.
Data management
All data are de-identified using participant numbers and
no session number is identified. Follow-up data is distin-
guished from baseline visit data with timestamps and
distinct variable names.
Source documents will be archived for 7 years beyond
study completion, or in accordance with IRB regulations,
whichever is longest.
Neuroimaging data are managed using the quality con-
trol and data management infrastructure at the Stanford
Center for Neurobiological Imaging (CNI). At CNI, the
Neurobiological Image Management System (NIMS) has
been in use for the past four years. The current version
of the software supports standardized format (DICOM)
files. NIMS was designed to address key issues in order
support the principles of reproducible research by i) en-
abling data sharing in way that is consistent with current
norms in the field of neuroscience and ii) combining im-
aging data and metadata about subjects in a searchable
database system.
For the computerized behavioral tests, the computer
registers each response and writes these with time
stamps to a log file. For the questionnaires, each self-
reported response entered by participants is logged.
These data are stored in a PHI-protected database and
then integrated with the neuroimaging data.
In accord with the requirements of the project funding
award, the data will be shared via the NIMH RDoC data-
base, RDoC-db.
Statistical analysis
The statistical analysis plan is designed to test specific
working hypotheses relevant to each of the primary aims
of the study:
1. We will use both a priori approaches to group
participants into “high” versus “low” subgroups on
each imaging circuit measure, and their combination.
We will also use data-derived techniques such as
cluster and factor analysis to complement these a
priori approaches.
We will use General Linear Models (GLMs) to
compare “high” versus “low” brain circuit-derived
subgroups and data-derived clusters on symptom
profiles. In correlational models we will assess the
relationships between brain imaging dimensions and
specific symptom profiles.
2. We will use GLMs to compare brain imaging-derived
subgroups/clusters on behavioral performance. We will
also test associations between behavior, imaging and
symptoms using correlational and mediator/moderator
models.
3. We will use GLMs to compare brain imaging-derived
subgroups/clusters on real-world function. We will
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also test associations between function, imaging,
behavior and symptoms using correlational and
mediator/moderator models.
The statistical analysis plan also addresses the secondary
aims of the study:
4. Repeated-measures GLMs, reliability and regression
models will be used to assess change (or stability) in
symptoms and function at follow-up and to test if
imaging at baseline predicts profiles of symptoms
and function after 12 weeks.
We will use multiple methods to integrate the data
under each aim.
As noted above we will use mediator and moderator
approaches to model the relationship between imaging,
symptoms, behavior and/or function at baseline and over
time.
Second, we will employ multiple methods for imple-
menting data reduction and pattern discovery, depending
on the dimensionality and distributions of data domains.
For example, we will employ model-based sparse factor
analysis [87], a method that has been developed and suc-
cessfully employed on functional neuroimaging data. We
will do so hierarchically, to find simple structure within
each domain separately, and then across domains, using
Bayesian Belief Nets [88] to obtain directed relationships.
We will also examine associations between domains using
modern variable selection techniques such as the Elastic
Net [89], a combined regression and variable selection
methodology that is capable of handling large numbers of
correlated explanatory variables. Finally, we will use tech-
niques such as canonical correlation analysis to determine
linear combinations of variables in given domains (e.g.,
neuroimaging) that maximally relate to variables in other
domains (e.g., behavioral or symptoms).
Power calculation
Power is estimated for GLMs assuming a small effect
size of Cohen’s f2 = 0.10. With 160 subjects (after drop-
out and exclusions) and with moderately correlated pre-
dictors (average r = .5) after multiple testing adjustments,
we have well over 80 % power to detect effect with
family-wise corrected alpha level of p < .05 [90].
Discussion
The project aligns tightly with the goals and units of
measurement defined by RDoC [10], to advance a neu-
robiologically informed understanding of mental dis-
orders. Currently our understanding of the brain basis
of anxiety and mood disorders is limited, especially at the
individual patient level. To our knowledge, no previous
study has characterized types of brain circuit dysfunctions
across disorders and then evaluated how these dysfunc-
tions relate to specific symptom profiles, behaviors and
real-world functioning. Defining these types of dysfunction
and relationships in a cohesive way will provide a founda-
tion for ultimately tailoring interventions to individual
needs.
We suggest that, to move forward in understanding the
mechanisms of anxiety and depression and potentially im-
prove quality of life, a shift is required to understanding
the brain circuit domains linked to observed symptoms,
behavior and function. Given that anxiety and depression
are so prevalent [1, 2] generate significant disability [3]
and we do not yet have biomarkers to help guide treat-
ment decisions in clinical settings this study addresses
an important public health need to understand these
disorders from a neurobiological rather than diagnostic
point of view – in order to better explain the mecha-
nisms by which dysfunction occurs and to better treat
these disorders.
Strengths and innovation of this project include the
use of mechanistically delineated paradigms for probing
brain circuits and behavior such that brain-based constructs
can be interpreted in the context of their behavioral expres-
sion as well as symptoms, the grounding in a conceptual
model that goes beyond simply emotion processing to cog-
nition and real world function, the use of well-established
standardized assessments, and the clinical partnership that
ensures recruitment of a sample representative of the com-
munity of people with anxiety and mood disorders.
Limitations and challenges
We are conscious that recruitment of participants from
community settings is a complex undertaking, which re-
quires us to consider the clinical priorities of therapists
and center supervisors. There is also a need to ensure
a smooth flow for testing visits and to minimize par-
ticipant burden. We have optimized the flow by using
standardized assessments that minimize assessment
time and by establishing a participant-friendly envir-
onment for the assessments. We also ensure that one
research coordinator maintains contact with each partici-
pant to individualize the experience and to maximize
retention in the study. Data collection will generate a
large volume of data, and we have sought to address
data management issues by establishing an efficient server
infrastructure.
Despite these challenges, the project is expected to
have an immediate impact on delineating the brain cir-
cuits and behavior that define cohesive constructs within
the spectrum of anxiety and mood disorders, resulting in
a new approach to diagnoses of anxiety and mood and
provide a foundation for future tailoring of treatments
to individual needs.
Williams et al. BMC Psychiatry  (2016) 16:68 Page 11 of 14
Endnotes
1The NIMH award title for this project is “Neural
dimensions of threat reactivity and regulation for un-
derstanding anxiety”
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